RIP 2 FAF

Related

• 

  Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials

  Karl G. Csaky, MD, PhD

  Updates from the Field

  2021

• 

  Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

  Dilsher S. Dhoot, MD

  On Demand Cases, Courses, and Papers

  2021

• 

  Imaging Pearls in AMD

  Netan Choudhry, MD, FRCS(C) FASRS

  Glenn J. Jaffe, MD

  Member Podcasts